Egl-9 family hypoxia inducible factor 1 messenger RNA (EGLN1 mRNA)

Egl-9 family hypoxia inducible factor 1 (EGLN1) messenger RNA, commonly known as PHD2 mRNA, is the transcript that encodes the primary oxygen-sensing enzyme in mammalian cells (NCBI Gene, 2024). Under normoxic conditions, the resulting PHD2 protein hydroxylates the Hypoxia-Inducible Factor (HIF) alpha subunit, marking it for ubiquitination and rapid proteasomal degradation (UniProt, 2024). Therapeutic targeting of the PHD2 mRNA transcript using RNA interference (siRNA) or antisense oligonucleotides (ASOs) aims to reduce the cellular concentration of the PHD2 enzyme, thereby inducing a state of 'pseudohypoxia' where HIF-1α and HIF-2α are stabilized. This stabilization triggers a coordinated transcriptional response that includes the production of erythropoietin (EPO) and pro-angiogenic factors like VEGF (PubMed, 2015). Consequently, PHD2 mRNA is a target of interest for treating anemia associated with chronic kidney disease and for promoting tissue repair in ischemic diseases such as peripheral arterial disease. While small molecule inhibitors like Roxadustat and Daprodustat target the PHD2 protein directly, mRNA-directed therapies represent an emerging modality for potentially more sustained or localized modulation of the hypoxia response pathway (Nature Reviews Drug Discovery, 2020).

Other names

PHD2 mRNAProlyl hydroxylase domain-containing protein 2 mRNAHIF-prolyl hydroxylase 2 mRNAHPH-2 mRNAHypoxia-inducible factor prolyl hydroxylase 2 mRNA

RNA interference (siRNA) or antisense-mediated knockdown of the mRNA transcript to prevent the translation of the PHD2 enzyme, thereby stabilizing Hypoxia-Inducible Factor (HIF) alpha subunits.